局部进展期直肠癌新辅助治疗后器官保留策略进展

doi:10.3760/cma.j.cn113030-20200515-00258

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (834 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Neoadjuvant chemoradiotherapy combined with total mesorectal excision is the standard treatment for stage T3-T4/N+ locally advanced rectal cancer (LARC). However, proctectomy is burdened with consistent postoperative morbidity, severely affecting the quality of life. “Organ preserving” methods could achieve similar oncological outcomes in highly selected patients whose tumors demonstrate (almost) clinical complete response to neoadjuvant treatment, while maintaining the quality of life and anorectal function by keeping the anus. This article aims to summarize the strategies of organ preservation after neoadjuvant treatment of LARC, salvage treatment for regrowth or recurrence, and anorectal function after organ preservation strategies.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Zhao Ying
	Tang Yuan
	Jin Jing

Key words： Rectal neoplasm Organ preservation Clinical complete response Watch and wait

Received: 15 May 2020

Corresponding Authors: Jin Jing, Email:jinjing@csco.org.cn

Cite this article:

Zhao Ying,Tang Yuan,Jin Jing. Advances in organ preservation for locally advanced rectal cancer after neoadjuvant chemoradiotherapy[J]. Chinese Journal of Radiation Oncology, 2022, 31(2): 208-213.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20200515-00258 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2022/V31/I2/208

[1] Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer[J]. N Engl J Med, 2004, 351(17):1731-1740. DOI:10.1056/NEJMoa040694.
[2] Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer:results of the German CAO/ARO/AIO-94 randomized phase Ⅲ trial after a median follow-up of 11 years[J]. J Clin Oncol, 2012, 30(16):1926-1933. DOI:10.1200/JCO.2011.40.1836.
[3] Paun BC, Cassie S, Maclean AR, et al. Postoperative complications following surgery for rectal cancer[J]. Ann Surg, 2010, 251(5):807-818. DOI:10.1097/SLA.0b013e3181 dae4ed.
[4] Ma B, Gao P, Wang H, et al. What has preoperative radio (chemo) therapy brought to localized rectal cancer patients in terms of perioperative and long-term outcomes over the past decades? A systematic review and meta-analysis based on 41,121 patients[J]. Int J Cancer, 2017, 141(5):1052-1065. DOI:10.1002/ijc.30805.
[5] Das P, Skibber JM, Rodriguez-Bigas MA, et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer[J]. Cancer, 2007, 109(9):1750-1755. DOI:10.1002/cncr.22625.
[6] Park IJ, You YN, Agarwal A, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer[J]. J Clin Oncol, 2012, 30(15):1770-1776. DOI:10.1200/JCO.2011.39.7901.
[7] Smith KD, Tan D, Das P, et al. Clinical significance of acellular mucin in rectal adenocarcinoma patients with a pathologic complete response to preoperative chemoradiation[J]. Ann Surg, 2010, 251(2):261-264. DOI:10.1097/SLA.0b013e3181bdfc27.
[8] Fokas E, Strbel P, Fietkau R, et al. Tumor regression grading after preoperative chemoradiotherapy as a prognostic factor and individual-level surrogate for disease-free survival in rectal cancer[J]. J Natl Cancer Inst, 2017, 109(12) DOI:10.1093/jnci/djx095.
[9] Karagkounis G, Thai L, Mace AG, et al. Prognostic implications of pathological response to neoadjuvant chemoradiation in pathologic stage Ⅲ rectal cancer[J]. Ann Surg, 2019, 269(6):1117-1123. DOI:10.1097/SLA.0000000000002719.
[10] Habr-Gama A, Perez RO, Wynn G, et al. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer:characterization of clinical and endoscopic findings for standardization[J]. Dis Colon Rectum, 2010, 53(12):1692-1698. DOI:10.1007/DCR.0b013e3181f42b89.
[11] Maas M, Lambregts DM, NelemansPJ, et al. Assessment of clinical complete response after chemoradiation for rectal cancer with digital rectal examination, endoscopy, and MRI:selection for organ-saving treatment[J]. Ann Surg Oncol, 2015, 22:3873-3880. DOI:10.1245/s10434-015-4687-9.
[12] Smith JJ, Chow OS, Gollub MJ, et al. Organ preservation in rectal adenocarcinoma:a phase Ⅱ randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management[J]. BMC Cancer, 2015, 15:767. DOI:10.1186/s12885-015-1632-z.
[13] Habr-Gama A, Perez RO, NadalinW, et al. Operative versus nonoperative treatment for stage 0distal rectal cancer following chemoradiation therapy:long-term results[J]. Ann Surg, 2004, 240(4):711-717;discussion 717-718. DOI:10.1097/01.sla.0000141194.27992.32.
[14] Habr-Gama A, Perez RO,So JulioGP, et al. Nonoperative approaches to rectal cancer:a critical evaluation[J]. SeminRadiat Oncol, 2011, 21(3):234-239. DOI:10.1016/j.semradonc.2011.02.010.
[15] Habr-Gama A, Gama-Rodrigues J,SoJulioGP, et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation:impact of salvage therapy on local disease control[J]. Int J Radiat Oncol Biol Phys, 2014, 88(4):822-828. DOI:10.1016/j.ijrobp.2013.12.012.
[16] Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer[J]. J Clin Oncol, 2011, 29(35):4633-4640. DOI:10.1200/JCO.2011.37.7176.
[17] Smith JD, Ruby JA, Goodman KA, et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy[J]. Ann Surg, 2012, 256(6):965-972. DOI:10.1097/SLA.0b013e3182759f1c.
[18] Smith JJ, Chow OS, Eaton A, et al. Organ preservation in patients with rectal cancer with clinical complete response after neoadjuvant therapy[J]. J Clin Oncol, 2015,33(3):509.
[19] Martens MH, Maas M, HeijnenLA, et al. Long-term outcome of an organ preservation program after neoadjuvant treatment for rectal cancer[J]. J Natl Cancer Inst, 2016, 108(12):171. DOI:10.1093/jnci/djw171.
[20] Renehan AG, Malcomson L, Emsley R, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project):a propensity-score matched cohort analysis[J]. Lancet Oncol, 2016, 17(2):174-183. DOI:10.1016/S1470-2045(15)00467-2.
[21] Dossa F, Chesney TR, Acuna SA, et al. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation:a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2017, 2(7):501-513. DOI:10.1016/S2468-1253(17)30074-2.
[22] Van Der Valk M, Hilling DE, BastiaannetE, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch& Wait Database (IWWD):an international multicentre registry study[J]. Lancet, 2018, 391(10139):2537-2545. DOI:10.1016/S0140-6736(18)31078-X.
[23] Smith JJ, Strombom P, Chow OS, et al. Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy[J]. JAMA Oncol, 2019, 5(4):e185896. DOI:10.1001/jamaoncol.2018.5896.
[24] Ellis CT, Dusetzina SB, Sanoff H, et al. Long-term survival after chemoradiotherapy without surgery for rectal adenocarcinoma:a word of caution[J]. JAMA Oncol, 2017, 3(1):123-125. DOI:10.1001/jamaoncol.2016.3424.
[25] Bujko K, Richter P, Smith FM, et al. Preoperative radiotherapy and local excision of rectal cancer with immediate radical re-operation for poor responders:a prospective multicentre study[J]. Radiother Oncol, 2013, 106(2):198-205. DOI:10.1016/j.radonc.2012.12.005.
[26] Pucciarelli S, De Paoli A, Guerrieri M, et al. Local excision after preoperative chemoradiotherapy for rectal cancer:results of a multicenter phase Ⅱ clinical trial[J]. Dis Colon Rectum, 2013, 56(12):1349-1356. DOI:10.1097/DCR.0b013e3182a2303e.
[27] Perez RO, Habr-Gama A, Lynn PB, et al. Transanal endoscopic microsurgery for residual rectal cancer (ypT0-2) following neoadjuvant chemoradiation therapy:another word of caution[J]. Dis Colon Rectum, 2013, 56(1):6-13. DOI:10.1097/DCR.0b013e318273f56f.
[28] Verseveld M, De Graaf EJ, Verhoef C, et al. Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery (CARTS study)[J]. Br J Surg, 2015,102(7):853-860. DOI:10.1002/bjs.9809.
[29] Stijns R, De Graaf E, Punt C, et al. Long-term oncological and functional outcomes of chemoradiotherapy followed by organ-sparing transanal endoscopic microsurgery for distal rectal cancer:the CARTS study[J]. JAMA Surg, 2019, 154(1):47-54. DOI:10.1001/jamasurg.2018.3752.
[30] Rullier E, Rouanet P, Tuech JJ, et al. Organ preservation for rectal cancer (GRECCAR 2):a prospective, randomised, open-label, multicentre, phase 3 trial[J]. Lancet, 2017,390(10093):469-479. DOI:10.1016/S0140-6736(17)31056-5.
[31] Rullier E, Vendrely V, AsselineauJ, et al. Organ preservation with chemoradiotherapy plus local excision for rectal cancer:5-year results of the GRECCAR 2 randomised trial[J]. Lancet Gastroenterol Hepatol, 2020, 5(5):465-474. DOI:10.1016/S2468-1253(19)30410-8.
[32] Yeom SS, Lee SY, Kim CH, et al. Non-operative treatment outcome for rectal cancer patient with clinical complete response after neoadjuvant chemoradiotherapy[J]. Asian J Surg, 2019, 42(8):823-831. DOI:10.1016/j.asjsur.2018.12.007.
[33] Smith FM, Ahad A, Perez RO, et al. Local excision techniques for rectal cancer after neoadjuvant chemoradiotherapy:what are we doing?[J]. Dis Colon Rectum, 2017,60(2):228-239. DOI:10.1097/DCR.0000000000000749.
[34] Perez RO, Habr-Gama A,SoJulioGP, et al. Transanal endoscopic microsurgery for residual rectal cancer after neoadjuvant chemoradiation therapy is associated with significant immediate pain and hospital readmission rates[J]. Dis Colon Rectum, 2011, 54(5):545-551. DOI:10.1007/DCR.0b013e3182083b84.
[35] Hayden DM, Jakate S, Pinzon MC, et al. Tumor scatter after neoadjuvant therapy for rectal cancer:are we dealing with an invisible margin?[J]. Dis Colon Rectum, 2012, 55(12):1206-1212. DOI:10.1097/DCR.0b013e318269fdb3.
[36] Perez RO, Habr-Gama A, Smith FM, et al. Fragmented pattern of tumor regression and lateral intramural spread may influence margin appropriateness after TEM for rectal cancer following neoadjuvant CRT[J]. J Surg Oncol, 2014,109(8):853-858. DOI:10.1002/jso.23571.
[37] Appelt AL, Plen J, Vogelius IR, et al. Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy[J]. Int J Radiat Oncol Biol Phys, 2013, 85(1):74-80. DOI:10.1016/j.ijrobp.2012.05.017.
[38] Appelt AL, Plen J, Harling H, et al. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer:a prospective observational study[J]. Lancet Oncol, 2015, 16(8):919-927. DOI:10.1016/S1470-2045(15)00120-5.
[39] Habr-Gama A, Sabbaga J, Gama-Rodrigues J, et al. Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer:are we getting closer to anal cancer management?[J]. Dis Colon Rectum, 2013, 56(10):1109-1117. DOI:10.1097/DCR.0b013e3182a25c4e.
[40] Gerard JP, Frin AC, Doyen J, et al. Organ preservation in rectal adenocarcinoma (T1) T2-T3 Nx M0. Historical overview of the Lyon Sud-nice experience using contact x-ray brachytherapy and external beam radiotherapy for 120 patients[J]. Acta Oncol, 2015, 54(4):545-551. DOI:10.3109/0284186X.2014.975840.
[41] Rijkmans EC, Cats A, Nout RA, et al. Endorectal brachytherapy boost after external beam radiation therapy in elderly or medically inoperable patients with rectal cancer:primary outcomes of the phase 1hERBERT study[J]. Int J Radiat Oncol Biol Phys, 2017, 98(4):908-917. DOI:10.1016/j.ijrobp.2017.01.033.
[42] Sunmyint A, Smith FM, Gollins SW, et al. Dose escalation using contact X-ray brachytherapy (Papillon) for rectal cancer:does it improve the chance of organ preservation?[J]. Br J Radiol, 2017, 90(1080):20170175. DOI:10.1259/bjr.20170175.
[43] Frin AC, Evesque L, Gal J, et al. Organ or sphincter preservation for rectal cancer. The role of contact X-ray brachytherapy in a monocentric series of 112 patients[J]. Eur J Cancer, 2017, 72:124-136. DOI:10.1016/j.ejca.2016.11.007.
[44] Sunmyint A, Smith FM, Gollins SW, et al. Dose escalation using contact X-ray brachytherapy after external beam radiotherapy as nonsurgical treatment option for rectal cancer:outcomes from a single-center experience[J]. Int J Radiat Oncol Biol Phys, 2018, 100(3):565-573. DOI:10.1016/j.ijrobp.2017.10.022.
[45] Gérard JP, Barbet N, Gal J, et al. Planned organ preservation for early T2-3 rectal adenocarcinoma:a French, multicentre study[J]. Eur J Cancer, 2019, 108:1-16. DOI:10.1016/j.ejca.2018.11.022.
[46] Garant A, Magnan S, Devic S, et al. Image guided adaptive endorectal brachytherapy in the nonoperative management of patients with rectal cancer[J]. Int J Radiat Oncol Biol Phys, 2019, 105(5):1005-1011. DOI:10.1016/j.ijrobp.2019.08.042.
[47] Lai CL, Lai MJ, Wu CC, et al. Rectal cancer with complete clinical response after neoadjuvant chemoradiotherapy, surgery, or"watch and wait"[J]. Int J Colorectal Dis, 2016,31(2):413-419. DOI:10.1007/s00384-015-2460-y.
[48] Pucciarelli S, Giandomenico F, De Paoli A, et al. Bowel function and quality of life after local excision or total mesorectal excision following chemoradiotherapy for rectal cancer[J]. Br J Surg, 2017, 104(1):138-147. DOI:10.1002/bjs.10318.
[49] Eid Y, Alves A, Lubrano J, et al. Does previous transanal excision for early rectal cancer impair surgical outcomes and pathologic findings of completion total mesorectal excision? Results of a systematic review of the literature[J]. J Visc Surg, 2018, 155(6):445-452. DOI:10.1016/j.jviscsurg.2018.03.008.
[50] Hupkens B, Martens MH, Stoot JH, et al. Quality of life in rectal cancer patients after chemoradiation:watch-and-wait policy versus standard resection-a matched-controlled study[J]. Dis Colon Rectum, 2017, 60(10):1032-1040. DOI:10.1097/DCR.0000000000000862.
[51] Garcia-Aguilar J, Renfro LA, Chow OS, et al. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041):results of an open-label, single-arm, multi-institutional, phase 2 trial[J]. Lancet Oncol, 2015, 16(15):1537-1546. DOI:10.1016/S1470-2045(15)00215-6.
[52] Dizdarevic E, Frstrup Hansen T, Plen J, et al. Long-term patient-reported outcomes after high-dose chemoradiation therapy for nonsurgical management of distal rectal cancer[J]. Int J Radiat Oncol Biol Phys, 2020, 106(3):556-563. DOI:10.1016/j.ijrobp.2019.10.046.